ArticleDiabetes, obesity & metabolism2026
Despite lower haemoglobin A1c with second-generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Emotional Burden and Behavioral Impacts of Alarms and Alerts Across the Spectrum of Diabetes Technology Use: a Cross-Sectional Study.JMIR diabetes · 2026Article
- Comparison of Glucose Management Between Open-Source Loop and Tandem Control-IQ Automated Insulin Delivery Systems in Adults With Type 1 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Automated insulin delivery system use and physical activity levels in adults with type 1 diabetes: A BETTER registry analysis.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- Despite lower haemoglobin A1c with second-generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis.Diabetes, obesity & metabolism · 2026Article
- Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.Hepatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveWe aim to compare second-generation automated insulin delivery systems (AIDs) with other treatment modalities regarding both glucose management outcomes and person-reported outcomes/experiences (PROs/PREs, measured by the Hypoglycemia Fear Survey, Hypoglycemic Confidence Scale, Hyperglycemia Avoidance Scale, Diabetes Distress Scale, Pittsburgh Sleep Quality Index, Well-being Scale, and treatment satisfaction) among adults with type 1 diabetes. RESEARCH DESIGN AND
methodsCross-sectional analysis of the Canadian BETTER type 1 diabetes registry. Adult participants were divided into five groups: second-generation AIDs, first-generation AIDs, continuous glucose monitoring (CGM) + pump, CGM + multiple daily injections (MDI), and non-CGM using MDI or pump. Generalized linear models were used to assess differences between the second-generation AID group and each of the other groups, with p < 0.05 considered significant.
resultsAmong 1731 participants (69.2% females), mean age was 45.3 ± 15.3 years with 24.7 ± 16.0 years of diabetes. The second-generation AID group had the highest proportion of achieving target haemoglobin A1c ≤ 7% (58.1%) compared to 40.6% in the first-generation AID group, 40.5% in the Pump + CGM group, 37.3% in the MDI + CGM group, and 32.3% in the non-CGM group, even after adjustment for multiple imbalanced characteristics (p < 0.001). While second-generation AID users reported higher treatment satisfaction, no other differences in measures of PROs/PREs were found between second-generation AID and other groups. Elevated diabetes distress (55%) and poor sleep quality (63%) remained common across all treatment groups, and even among those who had reached the optimal HbA1c target (48% and 60%, respectively).
conclusionsIn real-world settings, second-generation AIDs were associated with lower haemoglobin A1c and higher treatment satisfaction but not better PROs/PREs. Mental burden remained high despite the use of advanced diabetes technologies and optimal glucose management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.